应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
PLRZ Polyrizon Ltd.
休市中 10-23 16:00:00 EDT
8.73
+0.00
+0.05%
盘后
9.10
+0.37
+4.30%
19:57 EDT
最高
9.37
最低
8.73
成交量
1.63万
今开
8.93
昨收
8.72
日振幅
7.40%
总市值
2,119万
流通市值
1,860万
总股本
242.86万
成交额
14.76万
换手率
0.76%
流通股本
213.17万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Polyrizon完成Nasarix™研究临床中心网络建设,向患者入组迈进
美股速递 · 08-20
Polyrizon完成Nasarix™研究临床中心网络建设,向患者入组迈进
Polyrizon公布Nasarix™生物相容性项目成功结果,支持向首次人体临床试验迈进
美股速递 · 07-02
Polyrizon公布Nasarix™生物相容性项目成功结果,支持向首次人体临床试验迈进
Polyrizon与Arrow Aviation签署函件协议 将MOU下的排他期及初期谈判期延长至6月30日
美股速递 · 06-06
Polyrizon与Arrow Aviation签署函件协议 将MOU下的排他期及初期谈判期延长至6月30日
加载更多
公司概况
公司名称:
Polyrizon Ltd.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Polyrizon Ltd.于2005年1月在以色列注册成立。该公司是一家处于发展阶段的生物技术公司,专门开发以鼻喷雾剂形式交付的创新医疗器械水凝胶,该水凝胶在鼻腔内形成一层薄薄的基于水凝胶的防护屏障,可以防止病毒和过敏原接触鼻上皮组织。该公司的C&C水凝胶技术由天然存在的构建块的混合物组成,以鼻喷雾剂的形式提供,并可用作“生物面具”,在鼻腔内有一层薄薄的防护屏障。该公司正在进一步开发其专有的C&C水凝胶技术的某些方面,例如生物粘附性和在鼻腔沉积部位的延长保留时间,以用于鼻内给药。该公司将其专注于API鼻腔给药的独立平台技术称为T&T。
发行价格:
--
{"stockData":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":8.7251,"timestamp":1792785600000,"preClose":8.7204,"halted":0,"volume":16296,"hourTrading":{"tag":"盘后","latestPrice":9.1,"preClose":8.7251,"latestTime":"19:57 EDT","volume":2203,"amount":20214.7301,"timestamp":1792799867618,"change":0.3749,"changeRate":0.042968,"amplitude":0.117466},"delay":0,"changeRate":0.0005389661024723298,"floatShares":2131700,"shares":2428604,"eps":-3.127828,"marketStatus":"休市中","change":0.0047,"latestTime":"10-23 16:00:00 EDT","open":8.93,"high":9.37,"low":8.7251,"amount":147597.711912,"amplitude":0.073953,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.127828,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":8.7204,"postHourTrading":{"tag":"盘后","latestPrice":9.1,"preClose":8.7251,"latestTime":"19:57 EDT","volume":2203,"amount":20214.7301,"timestamp":1792799867618,"change":0.3749,"changeRate":0.042968,"amplitude":0.117466},"volumeRatio":1.1305675147966874},"requestUrl":"/m/hq/s/PLRZ","defaultTab":"news","newsList":[{"id":"1132297876","title":"Polyrizon完成Nasarix™研究临床中心网络建设,向患者入组迈进","url":"https://stock-news.laohu8.com/highlight/detail?id=1132297876","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132297876?lang=zh_cn&edition=full","pubTime":"2026-08-20 21:30","pubTimestamp":1787232625,"startTime":"0","endTime":"0","summary":"Polyrizon已成功构建Nasarix™研究的临床中心网络,并正稳步推进至患者入组阶段。这一里程碑式的进展,标志着该公司在鼻腔给药技术领域的研究又向前迈出了关键一步。随着临床站点网络的全面落成,Polyrizon现已具备启动患者招募工作的充分条件,为后续试验的顺利开展奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105819292","title":"Polyrizon公布Nasarix™生物相容性项目成功结果,支持向首次人体临床试验迈进","url":"https://stock-news.laohu8.com/highlight/detail?id=1105819292","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105819292?lang=zh_cn&edition=full","pubTime":"2026-07-02 19:37","pubTimestamp":1782992238,"startTime":"0","endTime":"0","summary":"Polyrizon公司宣布,其Nasarix™生物相容性项目已取得积极成果。这一关键进展有力地支持了该项目向首次人体临床试验阶段推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174404710","title":"Polyrizon与Arrow Aviation签署函件协议 将MOU下的排他期及初期谈判期延长至6月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=1174404710","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174404710?lang=zh_cn&edition=full","pubTime":"2026-06-06 04:25","pubTimestamp":1780691121,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. 与 Arrow Aviation 已正式签署一份函件协议。根据该协议,双方此前在谅解备忘录(MOU)框架下约定的排他性谈判期及初期谈判阶段,将一并延长至今年6月30日。此举旨在为双方就潜在合作事宜提供更充分的协商时间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.polyrizon-biotech.com","stockEarnings":[{"period":"1week","weight":-0.1275},{"period":"1month","weight":-0.2182},{"period":"3month","weight":-0.4056},{"period":"6month","weight":-0.4393},{"period":"1year","weight":0.3465},{"period":"ytd","weight":0.0277}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Polyrizon Ltd.于2005年1月在以色列注册成立。该公司是一家处于发展阶段的生物技术公司,专门开发以鼻喷雾剂形式交付的创新医疗器械水凝胶,该水凝胶在鼻腔内形成一层薄薄的基于水凝胶的防护屏障,可以防止病毒和过敏原接触鼻上皮组织。该公司的C&C水凝胶技术由天然存在的构建块的混合物组成,以鼻喷雾剂的形式提供,并可用作“生物面具”,在鼻腔内有一层薄薄的防护屏障。该公司正在进一步开发其专有的C&C水凝胶技术的某些方面,例如生物粘附性和在鼻腔沉积部位的延长保留时间,以用于鼻内给药。该公司将其专注于API鼻腔给药的独立平台技术称为T&T。","exchange":"NASDAQ","name":"Polyrizon Ltd.","nameEN":"Polyrizon Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Polyrizon Ltd.(PLRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Polyrizon Ltd.(PLRZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Polyrizon Ltd.,PLRZ,Polyrizon Ltd.股票,Polyrizon Ltd.股票老虎,Polyrizon Ltd.股票老虎国际,Polyrizon Ltd.行情,Polyrizon Ltd.股票行情,Polyrizon Ltd.股价,Polyrizon Ltd.股市,Polyrizon Ltd.股票价格,Polyrizon Ltd.股票交易,Polyrizon Ltd.股票购买,Polyrizon Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Polyrizon Ltd.(PLRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Polyrizon Ltd.(PLRZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}